No connection

Search Results

ABBV vs SILO

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
SILO
Silo Pharma, Inc.
BEARISH
Price
$0.52
Market Cap
$8.4M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
ABBV
163.63
SILO
--
Forward P/E
ABBV
15.42
SILO
-0.74
P/B Ratio
ABBV
-146.66
SILO
1.09
P/S Ratio
ABBV
6.5
SILO
116.19
EV/EBITDA
ABBV
15.27
SILO
-0.1

Profitability

Gross Margin
ABBV
71.46%
SILO
38.57%
Operating Margin
ABBV
35.5%
SILO
-4363.27%
Profit Margin
ABBV
4.0%
SILO
0.0%
ROE
ABBV
137.96%
SILO
-74.56%
ROA
ABBV
9.59%
SILO
-35.63%

Growth

Revenue Growth
ABBV
9.1%
SILO
0.0%
Earnings Growth
ABBV
-88.7%
SILO
--

Financial Health

Debt/Equity
ABBV
--
SILO
--
Current Ratio
ABBV
0.72
SILO
11.36
Quick Ratio
ABBV
0.47
SILO
10.55

Dividends

Dividend Yield
ABBV
3.05%
SILO
--
Payout Ratio
ABBV
490.15%
SILO
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
SILO BEARISH

SILO exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating a total lack of fundamental improvement across all measured categories. The company is currently pre-revenue or stagnant (0% YoY growth) with an unsustainable operating margin of -4363.27%. While a high current ratio of 11.36 suggests a temporary cash runway, the long-term trajectory is severely negative with a 5-year price decline of 96%. The recent 1-month price spike appears to be speculative volatility rather than a fundamental turnaround.

Strengths
Strong short-term liquidity (Current Ratio: 11.36)
Price/Book ratio near 1.09 suggests the stock is trading close to its accounting value
Recent short-term price momentum (+60.9% in 1 month)
Risks
Extreme fundamental weakness (Piotroski F-Score 0/9)
Zero revenue growth (YoY and Q/Q)
Massive operating losses (-4363.27% operating margin)

Compare Another Pair

ABBV vs SILO: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and Silo Pharma, Inc. (SILO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile